vendredi 4 janvier 2019

Onco Actu du 4 janvier 2019

1.2 BIOLOGIE - BIOBANQUES

Huge trove of British biodata is unlocking secrets of depression, sexual orientation, and more [Science]

2.6 ETIOLOGIE - ENVIRONNEMENT

U.S. judge limits evidence in trial over Roundup cancer claims [Reuters]

4.1 DÉP., DIAG. & PRONO. - PROSTATE

Mayo Clinic discovers biological markers that could guide treatment for prostate cancer [Mayo Clinic]

4.10 DÉP., DIAG. & PRONO. - POUMON

For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target [NCI]

5.10 TRAITEMENTS - ESSAIS

Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies [Boehringer Ingelheim]

5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS

Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance [Xconomy]

5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge [Xconomy]

5.12.5 IMMUNOTHÉRAPIES - PHARMA

Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio [Takeda]

Takeda builds arsenal for immuno-oncology research, creates cell therapy group [EndPoints]

5.12.6 IMMUNOTHÉRAPIES - AMM

Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors [Merck]

5.2.2 PHARMA - FUSIONS & ACQUISITIONS

Bristol-Myers Squibb and Celgene [In the Pipeline]

Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies [BiopharmaDive]

In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B [Xconomy]

Bristol-Myers scores first big deal of 2019 with $74B buyout of oncology bigwig Celgene [FiercePharma]

Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal [STAT]

Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong [Forbes]

Drug firm Bristol-Myers Squibb buys US rival Celgene in $74bn deal [The Guardian]

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion [NY Times]

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company [BMS]

The Claim By Bristol-Myers Squibb CEO That The New Company Will Be A 'Magnet For Talent' Is Naïve [Forbes]

Bristol-Myers Squibb buying Celgene in $74B deal [AP]

5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)

Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [BMS]

5.5 ASCO

ASCO to Convene Global Summit on Latest Innovations in Technology and Cancer [ASCO]

6.6 PUBLICATIONS

Poor Financials Pushes PLOS To Ponder Future Prospects [Scholarly Kitchen]

6.7 DMP, BIG DATA & APPLIS

Google is quietly infiltrating medicine — but what rules will it play by? [STAT]

6.7.3 DMP

Most U.S. patients not using online medical portals [Reuters]